TrialAmerican journal of hematology2020

A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.

Christopher Pleyer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.